Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Core Insights - PALI-2108 is a promising orally delivered, colon-specific PDE4 inhibitor prodrug for Ulcerative Colitis (UC) treatment, demonstrating safety, efficacy, and tolerability in preclinical studies [1][3][8] - The company plans to initiate Phase 1 human clinical trials for PALI-2108 by the end of 2024 [1] Preclinical Data - PALI-2108 showed a dose-dependent efficacy response in two DSS colitis mouse models, achieving results comparable to intolerable doses of apremilast for human use [1][8] - The study utilized an acute colitis model in mice, with treatments of PALI-2108 at doses of 20, 40, and 80 mg/kg administered twice daily, alongside cyclosporin A and apremilast [4][8] - Significant improvements were observed in body weight score, stool consistency score, fecal blood score, and overall disease activity index (DAI) score [8] Safety and Tolerability - PALI-2108 demonstrated no systemic toxicity in dogs, indicating a large therapeutic window due to its local activation [5][8] - The prodrug effectively prevented emesis that was observed with lower doses of the active PDE4 moiety, showcasing enhanced therapeutic potential [5] Company Overview - Palisade Bio is focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, aiming to transform treatment landscapes with targeted approaches [9]